Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Iterum Therapeutics plc (ITRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 2,155 7,332 Other income, net 50 269 91 431 Income tax expense Net loss $ $ $ $ Net loss per share – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,942,969 12,224,324 12,812,398 12,208,961 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortization 429 429 858 858 Share based compensation 110 1,984 503 3,879 Interest expense - accrued interest and amortization on Exchang..."
05/12/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 5,177 Other income, net 41 162 Income tax expense Net loss $ $ Net loss per share – basic and diluted $ $ Weighted average ordinary shares outstanding – basic and diluted 12,681,900 12,193,435 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ Intangible asset amortization 429 429 Share based compensation 393 1,895 Interest expense - accrued interest and amortization on Exchangeable Notes 783 783 Adjustments to fair value of derivatives 878 Non-GAAP net loss $ $ Net loss per share ..."
03/16/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations For the three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest income / , net 80 Adjustments to fair value of derivatives 2,960 3,562 5,458 Cancellation of share options - - - Other income, net 28 503 195 Income tax expense Net loss attributable to ordinary shareholders $ $ $ $ Net loss per share attributable to ordinary shareholders – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,294,865 12,185,019 12,236,607 10,891,178 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortiza..."
11/10/2022 8-K Quarterly results
Docs: "Investor Contact:"
08/12/2022 8-K Quarterly results
Docs: "Investor Contact:"
05/13/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results --Registration Trial for uUTI Planned in Second Half of 2022-- --Cash Runway into 2024— --Company to host conference call today at 8:30amET--"
11/12/2021 8-K Quarterly results
Docs: "Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update --Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem --"
08/13/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
11/16/2020 8-K Quarterly results
Docs: "Iterum Therapeutics Reports Third Quarter 2020 Financial Results --NDA Filing Expected Q4 2020--"
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "--Phase 3 Topline Data anticipated in the fourth quarter--"
05/14/2019 8-K Quarterly results
Docs: "Iterum Therapeutics Reports First Quarter 2019 Financial Results On track to complete enrollment in all three Phase 3 clinical trials before year-end Filed patent application that may extend Iterum’s intellectual property rights into the 2040s"
03/25/2019 8-K Quarterly results
Docs: "Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results"
11/14/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 14, 2018 Iterum Therapeutics plc Ireland 001-38503 98-1283148 Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland Registrant's telephone number, including area code: +353 1 903 8920 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act...",
"Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights"
08/14/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 14, 2018 Iterum Therapeutics plc Ireland 001-38503 98-1283148 Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland Registrant's telephone number, including area code: +353 1 903 8920 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act )...",
"Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy